* Aspira Women's Health Inc is expected to show a rise in quarterly revenue when it reports results on November 14 for the period ending September 30 2024

* The Austin Texas-based company is expected to report a 25.2% increase in revenue to $2.775 million from $2.22 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for Aspira Women's Health Inc is for a loss of 24 cents per share.

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Aspira Women's Health Inc is $4.25​, above​ its last closing price of $0.86. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jan. 1 0001 -0.31 -0.30 -0.28 Beat 8.2

Jan. 1 0001 -0.33 -0.33 -0.39 Missed -17.3

Dec. 31 2023 -0.39 -0.45 -0.30 Beat 33​

Jan. 1 0001 -0.45 -0.51 -0.48 Beat 5.4

​​Jun. -0.55 -0.55 -0.28 Beat 49.1

30 2023

Mar. 31 2023 -0.75 -0.75 -0.73 Beat 2.7​

Dec. 31 2022 -1.05 -0.97 38.5

Sep. 30 2022 -0.98 -0.97 -23.1

This summary was machine generated November 12 at 13:52 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)